Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
J GarauJ Rello

Abstract

The clinical and bacteriological efficacy and the tolerability of meropenem versus imipenem/cilastatin (both 1 g t.i.d.) in severe nosocomial infections were compared in a multicentre, randomised, nonblinded study. A total of 151 patients were recruited; 133 (66 meropenem, 67 imipenem/cilastatin) were clinically evaluable and 84 (42 meropenem, 42 imipenem/cilastatin) bacteriologically evaluable. Most clinically evaluable patients (90%) were in intensive care units, required mechanical ventilation (72%), and had received previous antibiotic therapy (62%). The mean (+/- SD) APACHE II score was 15.2 (+/- 6.6) in the meropenem group and 17.8 (+/- 6.8) in the imipenem/cilastatin group. The primary infections were nosocomial lower respiratory tract infections (56% of patients), intra-abdominal infections (15%), septicaemia (21%), skin/skin structure infections (5%), and complicated urinary tract infections (3%); 35% of the patients had two or more infections. There was no significant difference between the meropenem and imipenem/cilastatin groups in the rates of satisfactory clinical (weighted percentage 87% vs. 74%) or bacteriological (weighted percentage 79% vs. 71%) response. There was a slightly higher rate of clinical success wi...Continue Reading

References

Feb 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Nilsson-EhleS R Norrby
Sep 1, 1989·The Journal of Antimicrobial Chemotherapy·R C MoelleringD E Sentochnik
Sep 1, 1989·The Journal of Antimicrobial Chemotherapy·J B Patel, R E Giles
Sep 1, 1989·The Journal of Antimicrobial Chemotherapy·R P BaxS J Haworth
Sep 1, 1989·The Journal of Antimicrobial Chemotherapy·R N JonesC Thornsberry
Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Sep 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R E CondonS E Wilson
Jul 1, 1995·The Journal of Antimicrobial Chemotherapy·Y J Mouton, C Beuscart
Jul 1, 1995·The Journal of Antimicrobial Chemotherapy·D Sirot
Mar 20, 1996·JAMA : the Journal of the American Medical Association·J Y FagonC Gibert

❮ Previous
Next ❯

Citations

Jan 24, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Steven J EdwardsJonathan M Plumb
Jan 1, 2009·Neurocritical Care·Jason HoffmanGretchen M Brophy
Nov 19, 2003·The Journal of Hospital Infection·R MastertonG Park
Jun 23, 1998·Diagnostic Microbiology and Infectious Disease·J Garau
Feb 19, 2002·International Journal of Antimicrobial Agents·Bekir S Kocazeybek, Umit Arabaci
Aug 26, 1998·International Journal of Antimicrobial Agents·B A Cunha
Apr 30, 1999·International Journal of Antimicrobial Agents·J S BradleyJ P Quinn
Dec 14, 1999·International Journal of Antimicrobial Agents·P J TurnerJ McKellar
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RubinsteinUNKNOWN Linezolid Nosocomial Pneumonia Study Group
Jul 30, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Donald R GrahamCynthia L Fowler
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emil LeshoDavid Craft
Sep 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John F Mohr
Nov 16, 2004·Critical Care Medicine·Pierre-Yves BochudThierry Calandra
May 23, 2002·Antimicrobial Agents and Chemotherapy·Sergei B VakulenkoStephen A Lerner
May 25, 2004·Antimicrobial Agents and Chemotherapy·Florian TomaselliPeter Dittrich
Mar 25, 2008·Therapeutics and Clinical Risk Management·Douglas N Fish
Jun 28, 2003·American Journal of Veterinary Research·Corrie W BarkerM A McCrackin Stevenson
Apr 20, 2014·The Journal of Antimicrobial Chemotherapy·Joan P CannonShellee A Grim
Jun 23, 2005·Current Medical Research and Opinion·Steven J EdwardsHelen E Campbell
Mar 10, 2001·Journal of Chemotherapy·F Alvarez Lerma, UNKNOWN Serious Infection Study Group
Aug 31, 2004·Journal of Chemotherapy·S J BermanUNKNOWN Merrem Hospital-Acquired Pneumonia Study Group
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Ioannis P KioumisDavid P Nicolau
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Diogo Diniz Gomes BuganoEliezer Silva
Mar 4, 2008·Expert Opinion on Pharmacotherapy·Jomy Joseph, Keith A Rodvold
Apr 2, 2002·Expert Opinion on Investigational Drugs·Giovanni BonfiglioGiuseppe Nicoletti
Dec 29, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Xiuwen WuJianan Ren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.